GPs in South West London have been invited to sign-up to a new Local Enhanced Service for initiation and management of tirzepatide (Mounjaro®) in primary care for patients who meet the eligibility criterion according to the NHSE interim commissioning guidance. 

​

Tirzepatide is a long-acting GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist that increases insulin sensitivity and secretion, suppresses glucagon secretion, and slows gastric emptying. ​​

​

In order to better support practices, the ICB have prepared a schedule of training sessions, Resources and FAQs.